zidovudine + zalcitabine + interferon alfa-n1

zidovudine + zalcitabine + interferon alfa-n1 is a **three-drug combination regimen** used for treatment of HIV-1 infection. This combination consists of **zidovudine** (a nucleoside reverse transcriptase inhibitor), **zalcitabine** (a nucleoside reverse transcriptase inhibitor), and **interferon alfa-n1** (a recombinant or native interferon alpha, classified as a cytokine). - **Zidovudine** and **zalcitabine** work by inhibiting the HIV reverse transcriptase enzyme, preventing viral replication. - **Interferon alfa-n1** exhibits antiviral, immunomodulatory, and antiproliferative activity through activation of interferon-stimulated genes, enhancing immune responses against the virus and directly inhibiting viral replication. - Clinical studies have shown that adding interferon alfa to zidovudine and zalcitabine provides greater inhibition of HIV-1 replication and transient reductions in viral load, but increases toxicity (notably neutropenia, anemia, and peripheral neuropathy) and may attenuate CD4+ cell response relative to dual therapy[1][2]. - Used primarily in HIV-infected individuals with moderate immune suppression (CD4+ counts between 300–500 cells/mm³), with short prior antiretroviral exposure[1]. - This regimen was investigated in the 1990s and is **not a current standard of care**, as newer antiretroviral combinations have superior efficacy and tolerability.